Yuanyan Pharmaceutical Port Life Science Research (Liaoning) Co., Ltd.

Part A: Primary Study Objective: To evaluate the pharmacokinetics of MT-1207 extended-release tablets with single and multiple dose escalations in healthy subjects. Secondary Study Objectives: To evaluate the safety and tolerability of MT-1207 extended-release tablets with single and multiple dose escalations in healthy subjects; to evaluate the effect of food on the pharmacokinetics of MT-1207 extended-release tablets in healthy subjects. Part B: Primary Study Objective: To evaluate the safety and tolerability of MT-1207 extended-release tablets with multiple doses in patients with mild to moderate hypertension. Secondary Study Objective: To evaluate the pharmacokinetic characteristics of MT-1207 extended-release tablets with multiple doses in patients with mild to moderate hypertension. Exploratory Study Objective: To evaluate the efficacy of MT-1207 extended-release tablets with multiple doses in patients with mild to moderate hypertension.

Using placebo as control, explore the effectiveness of different doses of PE-001 tablets in treating male subjects with premature ejaculation;

A randomized, double-blind, placebo- and active drug-controlled, multicenter Phase II clinical trial of the efficacy and safety of MT-1207 tablets in the treatment of mild and moderate essential hypertension